Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 1/20 | 0.70 |
| ▸ | XDH | P47989 | 5/20 | 0.61 |
| ▸ | SLC22A12 | Q96S37 | 5/20 | 0.61 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.44 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.42 |
| ▸ | CD38 | P28907 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4185259 | 0.85 | XDH (0.67) | TDP2XDHSLC22A12SOS1RAPGEF4 | |
| SCHEMBL4187369 | 0.83 | XDH (0.57) | TDP2XDHSLC22A12 | |
| SCHEMBL4189069 | 0.82 | TDP2 (0.62) | TDP2XDHSLC22A12SOS1EGFR | |
| SCHEMBL4191826 | 0.81 | TDP2 (0.61) | TDP2XDHSLC22A12MAPK1SOS1 | |
| SCHEMBL4194098 | 0.81 | XDH (0.64) | TDP2XDHSLC22A12RAPGEF4MEN1 | |
| SCHEMBL4185419 | 0.81 | TDP2 (0.61) | TDP2XDHSLC22A12SOS1EGFR | |
| SCHEMBL4185498 | 0.79 | TDP2 (0.59) | TDP2XDHSLC22A12GRM4MAPK1 | |
| SCHEMBL4183083 | 0.79 | TDP2 (0.59) | TDP2XDHSLC22A12SOS1EGFR | |
| SCHEMBL4194356 | 0.79 | TDP2 (0.58) | TDP2XDHSLC22A12EGFRMEN1 | |
| SCHEMBL4187735 | 0.79 | TDP2 (0.58) | TDP2XDHSLC22A12EGFRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090196912-A1 | Pyridinylamines | GPC BOTECH AG (DE) | 2009-08-06 | — | — | US | claimed |
| EP-1789393-A2 | PYRIDINYLAMINES | GPC Biotech AG (DE) | 2007-05-30 | — | — | EP | claimed |
| WO-2006010637-A2 | PYRIDINYLAMINES | GPC BIOTECH AG (DE) | 2006-02-02 | — | — | WO | claimed |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2020-07-02 | — | — | US | disclosed |
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | BROWN DENNIS M (US) | 2019-08-20 | — | — | US | disclosed |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2016-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | NEK9, NEK7, NEK3 | TDP2 1940/4885XDH 1630/4885SLC22A12 3973/4885 |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | TDP2 1940/4885XDH 1630/4885SLC22A12 3973/4885 |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | TDP2 1940/4885XDH 1630/4885SLC22A12 3973/4885 |
| US-20090196912-A1 | Pyridinylamines | PRNP, PLPBP, SNCA | TDP2 135/4885XDH 527/4885SLC22A12 2928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.